Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer

Lori E. Eichelberger, Michael Koch, John Eble, Thomas Ulbright, Beth E. Juliar, Liang Cheng

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Maximum tumor diameter has been shown to correlate with multiple predictors of clinical outcome in prostate cancer. In the current study, we prospectively analyze whether maximum tumor diameter is a significant predictor of prostate-specific antigen (PSA) recurrence. The study population consisted of 364 patients who underwent radical prostatectomy for prostate cancer. Prostatectomy specimens were evaluated by whole-mount processing of the entire prostate. Maximum tumor diameter was measured from the whole-mount sections of the prostate. Spearman's coefficient of rank correlation was used to correlate tumor diameter with continuous variables. T-tests or analysis of variance (ANOVA) tests were performed to determine if tumor diameter was significantly associated with other clinical and pathologic variables. The effect of clinical and pathologic variables on time to recurrence was analyzed using Cox regression. The mean tumor diameter for all patients was 1.73 cm (range, 0.02-4.40 cm). Maximum tumor diameter was associated with preoperative PSA (r = 0.22, P < 0.0001), prostate weight (r = -0.12, P = 0.028), tumor volume (r = 0.87, P < 0.0001), Gleason score (r = 0.29, P < 0.0001), and pathologic stage (P < 0.0001). Cox multiple regression was performed to test the prognostic value of maximum tumor diameter adjusting for pathologic stage, Gleason score, and surgical margin status. Increased maximum tumor diameter was associated with shorter time to PSA recurrence (hazard ratio = 1.70, 95% confidence interval 1.13-2.56, P = 0.01), controlling for risk factors, Gleason score, and surgical margin status. We conclude that maximum tumor diameter is a significant predictor of biochemical recurrence in patients with prostate cancer.

Original languageEnglish
Pages (from-to)886-890
Number of pages5
JournalModern Pathology
Volume18
Issue number7
DOIs
StatePublished - Jul 2005

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Recurrence
Neoplasms
Neoplasm Grading
Prostate
Prostatectomy
Nonparametric Statistics
Tumor Burden
Analysis of Variance
Confidence Intervals
Weights and Measures

Keywords

  • Neoplasm
  • Prostate
  • Prostatectomy
  • PSA recurrence
  • TNM staging
  • Tumor diameter
  • Tumor length
  • Tumor volume

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. / Eichelberger, Lori E.; Koch, Michael; Eble, John; Ulbright, Thomas; Juliar, Beth E.; Cheng, Liang.

In: Modern Pathology, Vol. 18, No. 7, 07.2005, p. 886-890.

Research output: Contribution to journalArticle

@article{bef982049fed47ffb839f8b368f6f6ca,
title = "Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer",
abstract = "Maximum tumor diameter has been shown to correlate with multiple predictors of clinical outcome in prostate cancer. In the current study, we prospectively analyze whether maximum tumor diameter is a significant predictor of prostate-specific antigen (PSA) recurrence. The study population consisted of 364 patients who underwent radical prostatectomy for prostate cancer. Prostatectomy specimens were evaluated by whole-mount processing of the entire prostate. Maximum tumor diameter was measured from the whole-mount sections of the prostate. Spearman's coefficient of rank correlation was used to correlate tumor diameter with continuous variables. T-tests or analysis of variance (ANOVA) tests were performed to determine if tumor diameter was significantly associated with other clinical and pathologic variables. The effect of clinical and pathologic variables on time to recurrence was analyzed using Cox regression. The mean tumor diameter for all patients was 1.73 cm (range, 0.02-4.40 cm). Maximum tumor diameter was associated with preoperative PSA (r = 0.22, P < 0.0001), prostate weight (r = -0.12, P = 0.028), tumor volume (r = 0.87, P < 0.0001), Gleason score (r = 0.29, P < 0.0001), and pathologic stage (P < 0.0001). Cox multiple regression was performed to test the prognostic value of maximum tumor diameter adjusting for pathologic stage, Gleason score, and surgical margin status. Increased maximum tumor diameter was associated with shorter time to PSA recurrence (hazard ratio = 1.70, 95{\%} confidence interval 1.13-2.56, P = 0.01), controlling for risk factors, Gleason score, and surgical margin status. We conclude that maximum tumor diameter is a significant predictor of biochemical recurrence in patients with prostate cancer.",
keywords = "Neoplasm, Prostate, Prostatectomy, PSA recurrence, TNM staging, Tumor diameter, Tumor length, Tumor volume",
author = "Eichelberger, {Lori E.} and Michael Koch and John Eble and Thomas Ulbright and Juliar, {Beth E.} and Liang Cheng",
year = "2005",
month = "7",
doi = "10.1038/modpathol.3800405",
language = "English",
volume = "18",
pages = "886--890",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer

AU - Eichelberger, Lori E.

AU - Koch, Michael

AU - Eble, John

AU - Ulbright, Thomas

AU - Juliar, Beth E.

AU - Cheng, Liang

PY - 2005/7

Y1 - 2005/7

N2 - Maximum tumor diameter has been shown to correlate with multiple predictors of clinical outcome in prostate cancer. In the current study, we prospectively analyze whether maximum tumor diameter is a significant predictor of prostate-specific antigen (PSA) recurrence. The study population consisted of 364 patients who underwent radical prostatectomy for prostate cancer. Prostatectomy specimens were evaluated by whole-mount processing of the entire prostate. Maximum tumor diameter was measured from the whole-mount sections of the prostate. Spearman's coefficient of rank correlation was used to correlate tumor diameter with continuous variables. T-tests or analysis of variance (ANOVA) tests were performed to determine if tumor diameter was significantly associated with other clinical and pathologic variables. The effect of clinical and pathologic variables on time to recurrence was analyzed using Cox regression. The mean tumor diameter for all patients was 1.73 cm (range, 0.02-4.40 cm). Maximum tumor diameter was associated with preoperative PSA (r = 0.22, P < 0.0001), prostate weight (r = -0.12, P = 0.028), tumor volume (r = 0.87, P < 0.0001), Gleason score (r = 0.29, P < 0.0001), and pathologic stage (P < 0.0001). Cox multiple regression was performed to test the prognostic value of maximum tumor diameter adjusting for pathologic stage, Gleason score, and surgical margin status. Increased maximum tumor diameter was associated with shorter time to PSA recurrence (hazard ratio = 1.70, 95% confidence interval 1.13-2.56, P = 0.01), controlling for risk factors, Gleason score, and surgical margin status. We conclude that maximum tumor diameter is a significant predictor of biochemical recurrence in patients with prostate cancer.

AB - Maximum tumor diameter has been shown to correlate with multiple predictors of clinical outcome in prostate cancer. In the current study, we prospectively analyze whether maximum tumor diameter is a significant predictor of prostate-specific antigen (PSA) recurrence. The study population consisted of 364 patients who underwent radical prostatectomy for prostate cancer. Prostatectomy specimens were evaluated by whole-mount processing of the entire prostate. Maximum tumor diameter was measured from the whole-mount sections of the prostate. Spearman's coefficient of rank correlation was used to correlate tumor diameter with continuous variables. T-tests or analysis of variance (ANOVA) tests were performed to determine if tumor diameter was significantly associated with other clinical and pathologic variables. The effect of clinical and pathologic variables on time to recurrence was analyzed using Cox regression. The mean tumor diameter for all patients was 1.73 cm (range, 0.02-4.40 cm). Maximum tumor diameter was associated with preoperative PSA (r = 0.22, P < 0.0001), prostate weight (r = -0.12, P = 0.028), tumor volume (r = 0.87, P < 0.0001), Gleason score (r = 0.29, P < 0.0001), and pathologic stage (P < 0.0001). Cox multiple regression was performed to test the prognostic value of maximum tumor diameter adjusting for pathologic stage, Gleason score, and surgical margin status. Increased maximum tumor diameter was associated with shorter time to PSA recurrence (hazard ratio = 1.70, 95% confidence interval 1.13-2.56, P = 0.01), controlling for risk factors, Gleason score, and surgical margin status. We conclude that maximum tumor diameter is a significant predictor of biochemical recurrence in patients with prostate cancer.

KW - Neoplasm

KW - Prostate

KW - Prostatectomy

KW - PSA recurrence

KW - TNM staging

KW - Tumor diameter

KW - Tumor length

KW - Tumor volume

UR - http://www.scopus.com/inward/record.url?scp=23044497683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044497683&partnerID=8YFLogxK

U2 - 10.1038/modpathol.3800405

DO - 10.1038/modpathol.3800405

M3 - Article

VL - 18

SP - 886

EP - 890

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 7

ER -